# MOPTIM

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/moptim

- Industry: Medical Devices & Equipment
- Headquarters: Shenzhen, China
- Website: www.certainn.com
- Total disclosed funding: $15M
- Latest round: Series B (Apr 7, 2026)
- Investors on record: 3

## About

Based in Shenzhen, China, and founded in 2003, Shenzhen Moting Medical Technology Co., Ltd., trading as MOPTIM, operates as a medical equipment company, engaged in the R & D, production and sales of optical medical equipment. The company has marketing offices in Guangzhou, Shanghai, Beijing, and Wuhan. In 2004, the company started technical cooperation with Tsinghua University for the industrialization of OCT technology. In 2005, the company founded an R&D subsidiary, Shenzhen MOPTIM Imaging Technology Co., Ltd. 
In April 2026, MOPTIM raised approximately CNY 100 million in series B funding led by China Venture Capital, with participation from CAS Investment Management and Baidu Ventures.
The company's products can be categorized into Ophthalmic OCT, optometry products, operating microscope, non-contact tonometer, gynecological products, and non-medical products. Some of the main products within the OCT category include ophthalmic optical coherence tomography, and optical biometric instruments. Its Master OCT not only has day after anterior segment OCT and OCT data acquisition and analysis function. It can be applied in the field of ophthalmology examination, LASIK surgery, cataract, and adolescent myopia prevention and control.
The company's revenue is generated by providing ophthalmic medical equipments.
The series B round of funding will be used for the iteration of core underlying optical technologies, expansion of high-end intelligent manufacturing capacity, and AI algorithm upgrades. It will also comprehensively promote the large-scale deployment of products in primary healthcare in China and in the global market, leveraging cutting-edge technology to support the national healthcare infrastructure development project and drive China's high-end ophthalmic devices onto the world stage.

## Funding rounds

- Series B, Apr 7, 2026, $15M — CAS Investment Management, China Venture Capital, Baidu Ventures
- Series A, Mar 14, 2022 — Baidu Ventures
- Series A, Jan 18, 2021 — CAS Investment Management

## Investors

- CAS Investment Management (https://capitalatlas.ai/funds/cas-investment-management) — Series A, Series B
- Baidu Ventures (https://capitalatlas.ai/funds/baidu-ventures) — Series A, Series B
- China Venture Capital (https://capitalatlas.ai/funds/china-venture-capital) — Series B